ManishSharmaMD

Oncology • Grand Rapids, MI

Hematologic Oncology, Clinical Pharmacology

Co-Director of Clinical Research, START Midwest

Join to view full profile

Dr. Sharma is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sharma's full profile

Already have an account?

Office
5800 Foremost Dr SE
Grand Rapids, MI 49546
Phone+1 616-954-5554

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2008 - 2011
University of California (San Francisco)Residency, Internal Medicine, 2004 - 2008
University of Michigan Medical SchoolClass of 2004

Certifications & Licensure

CA State Medical License 2006 - Present
MI State Medical License 2018 - 2025
IL State Medical License 2008 - 2020
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients Start of enrollment: 2009 Dec 12
Completed
Phase 1
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies Start of enrollment: 2012 Aug 29
Terminated
Phase 1
Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery Start of enrollment: 2012 Jun 13
Completed
Phase 1
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Start of enrollment: 2013 Sep 20
Active, not recruiting
Phase 2
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy Start of enrollment: 2013 Jul 08
Active, not recruiting
Phase 2
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer Start of enrollment: 2014 Apr 01
Completed
Phase 1
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors Start of enrollment: 2014 Apr 01
Completed
Phase 1
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2014 Aug 25
Completed
Phase 2
Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer Start of enrollment: 2015 Jun 01
Withdrawn
Phase 1
MGC018 With or Without MGA012 in Advanced Solid Tumors Start of enrollment: 2018 Nov 21
Terminated
Phase 1, Phase 2
Study of CPI-200 in Patients With Advanced Tumors Start of enrollment: 2019 Jul 01
Completed
Phase 1
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors Start of enrollment: 2020 Jan 23
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

57 citations
Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma.
Ravi Vij, Shaji Kumar, Mei-Jie Zhang, Xiaobo Zhong, Jiaxing Huang
Biology of Blood and Marrow Transplantation. 2015-02-01
78 citations
Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.
Ayman Saad, Anuj Mahindra, Mei-Jie Zhang, Xiaobo Zhong, Luciano J. Costa
Biology of Blood and Marrow Transplantation. 2014-03-01
408 citations
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
Jason J. Luke, Jeffrey Lemons, Theodore Karrison, Sean P. Pitroda, J.M. Melotek
Journal of Clinical Oncology. 2018-02-13

Lectures

Impact and influence of PET on imaging related endpoints in patients with Lymphoma using IWG-NHL or Lugano classification.
2019 ASCO Annual Meeting - 6/1/2019